
Global Biobanking Market Report and Forecast 2024-2032
Description
Global Biobanking Market Report and Forecast 2024-2032
Global Biobanking Market Report and Forecast 2024-2032
The global biobanking market size was valued at USD 72.1 billion in 2023. It is projected to expand at a CAGR of 6.89% throughout the forecast period from 2024 to 2032, driven by technological innovations and a rising prevalence of injuries across the globe. It is projected to attain a value of USD 131.1 billion by 2032.
Global Biobanking Market Analysis
The global biobanking market has been witnessing significant growth and is poised to continue expanding from 2017 to 2032. This expansion is driven by a combination of factors, each playing a crucial role in shaping the landscape of biobanking. These factors include technological advancements, regulatory landscapes, the growing prevalence of chronic diseases, the rise in biobanking applications, and shifts in funding and investment patterns.
Global Biobanking Market Trends
The global biobanking market has experienced a notable trajectory of growth and transformation between 2017 and 2032, driven by multifaceted trends that reflect advancements in technology, evolving regulatory frameworks, and shifting priorities in medical research and healthcare. These trends not only underscore the expanding role of biobanks in supporting medical research and development but also highlight the challenges and opportunities faced by this sector. Below are the key market trends that have characterized the global biobanking market over this period:
- Accelerated Technological Integration
- Emphasis on Precision Medicine
- Regulatory and Ethical Evolution
- Expansion of Biobanking Applications
- Geographic Diversification
- Sustainable Funding Models
- Focus on Patient Engagement and Consent
Global Biobanking Market Segmentation
Market Breakup by Material
- Population-based Biobanks
- Disease-based Biobanks
- Academic Biobanks
- Hospital-based Biobanks
- Commercial Biobanks
Market Breakup by Sample Type
- Blood Products
- Human Tissues
- Nucleic Acids
- Cell Lines
- Biological Fluids
- Others
Market Breakup by Application
- Drug Discovery and Development
- Personalized Medicine
- Regenerative Medicine
- Clinical Research
- Forensics
- Others
Clinical Research benefits from biobanked samples to conduct studies on disease mechanisms, treatment outcomes, and epidemiological insights. Forensics uses biobanked DNA and other samples for identification purposes and in solving crimes. The "Others" category encompasses additional applications such as biomarker discovery, nutritional research, and environmental health studies. This segmentation underscores the multifaceted contributions of biobanking to various fields, reflecting its integral role in advancing medical science and improving patient care.
Market Breakup by Ownership
- Public Biobanks
- Private Biobanks
- Hybrid Biobanks
Market Breakup by Source
- Human Biobanks
- Animal Biobanks
- Plant Biobanks
Market Breakup by End User
- Biopharmaceutical Companies
- Research and Academic Institutes
- Hospitals
- Contract Research Organizations (CROs)
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Biobanking Market Competitive Landscape
The global biobanking market is highly fragmented and competitive, with the presence of several players, such as Thermo Fisher Scientific Inc., Brooks Automation, Inc., Qiagen N.V., Tecan Group Ltd., Hamilton Company, Chart Industries, Inc., PHC Holdings Corporation, Becton, Dickinson and Company (BD), Panasonic Healthcare Holdings Co., Ltd., STEMCELL Technologies Inc., Lifenet Health, Promega Corporation, Greiner Bio-One International GmbH, Lonza Group AG. These players are engaged in various strategies, such as product launches and enhancements, mergers and acquisitions, partnerships and collaborations, and expansions and investments, to gain a competitive edge and increase their market share.
Key Questions Answered in This Report
- How did the biobanking market perform globally from 2017 to 2023, and what are the forecasts for its growth until 2032?
- What technological innovations have had a major impact on the biobanking market?
- How do key drivers, restraints, and opportunities affect the biobanking market?
- Which regions are the key markets in the global biobanking scenario?
- Which countries are emerging as the most promising markets for biobanking?
- How is the biobanking market segmented by the material of biobank?
- Which source of biobank is the most valuable for veterinary and pharmaceutical research?
- How is the biobanking market divided by the type of samples application and ownership?
- How is the competitive landscape shaped in the biobanking market?
- Who are the leading companies and organizations in the biobanking market?
- The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the biobanking market from 2017-2032.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the global biobanking market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the biobanking industry and its attractiveness.
- The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Biobanking Market Overview
- 3.1 Global Biobanking Market Historical Value (2017-2023)
- 3.2 Global Biobanking Market Forecast Value (2024-2032)
- 4 Global Biobanking Market Landscape*
- 4.1 Global Biobanking: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Biobanking: Product Landscape
- 4.2.1 Analysis by Material
- 4.2.2 Analysis by Sample Type
- 5 Global Biobanking Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Biobanking Market Segmentation (2017-2032)
- 6.1 Global Biobanking Market (2017-2032) by Material
- 6.1.1 Market Overview
- 6.1.2 Population-based Biobanks
- 6.1.3 Disease-based Biobanks
- 6.1.4 Academic Biobanks
- 6.1.5 Hospital-based Biobanks
- 6.1.6 Commercial Biobanks
- 6.2 Global Biobanking Market (2017-2032) by Sample Type
- 6.2.1 Market Overview
- 6.2.2 Blood Products
- 6.2.3 Human Tissues
- 6.2.4 Nucleic Acids
- 6.2.5 Cell Lines
- 6.2.6 Biological Fluids
- 6.2.7 Others
- 6.3 Global Biobanking Market (2017-2032) by Application
- 6.3.1 Market Overview
- 6.3.2 Drug Discovery and Development
- 6.3.3 Personalized Medicine
- 6.3.4 Regenerative Medicine
- 6.3.5 Clinical Research
- 6.3.6 Forensics
- 6.3.7 Others
- 6.4 Global Biobanking Market (2017-2032) by Ownership
- 6.4.1 Market Overview
- 6.4.2 Public Biobanks
- 6.4.3 Private Biobanks
- 6.4.4 Hybrid Biobanks
- 6.5 Global Biobanking Market (2017-2032) by Source
- 6.5.1 Market Overview
- 6.5.2 Human Biobanks
- 6.5.3 Animal Biobanks
- 6.5.4 Plant Biobanks
- 6.6 Global Biobanking Market (2017-2032) by End User
- 6.6.1 Market Overview
- 6.6.2 Biopharmaceutical Companies
- 6.6.3 Research and Academic Institutes
- 6.6.4 Hospitals
- 6.6.5 Contract Research Organizations (CROs)
- 6.6.6 Others
- 6.7 Global Biobanking Market (2017-2032) by Region
- 6.7.1 Market Overview
- 6.7.2 North America
- 6.7.3 Europe
- 6.7.4 Asia Pacific
- 6.7.5 Latin America
- 6.7.6 Middle East and Africa
- 7 North America Biobanking Market (2017-2032)
- 7.1 North America Biobanking Market (2017-2032) by Material
- 7.1.1 Market Overview
- 7.1.2 Population-based Biobanks
- 7.1.3 Disease-based Biobanks
- 7.1.4 Academic Biobanks
- 7.1.5 Hospital-based Biobanks
- 7.1.6 Commercial Biobanks
- 7.2 North America Biobanking Market (2017-2032) by Sample Type
- 7.2.1 Market Overview
- 7.2.2 Blood Products
- 7.2.3 Human Tissues
- 7.2.4 Nucleic Acids
- 7.2.5 Cell Lines
- 7.2.6 Biological Fluids
- 7.2.7 Others
- 7.3 North America Biobanking Market (2017-2032) by Country
- 7.3.1 United States of America
- 7.3.2 Canada
- 8 Europe Biobanking Market (2017-2032)
- 8.1 Europe Biobanking Market (2017-2032) by Material
- 8.1.1 Market Overview
- 8.1.2 Population-based Biobanks
- 8.1.3 Disease-based Biobanks
- 8.1.4 Academic Biobanks
- 8.1.5 Hospital-based Biobanks
- 8.1.6 Commercial Biobanks
- 8.2 Europe Biobanking Market (2017-2032) by Sample Type
- 8.2.1 Market Overview
- 8.2.2 Blood Products
- 8.2.3 Human Tissues
- 8.2.4 Nucleic Acids
- 8.2.5 Cell Lines
- 8.2.6 Biological Fluids
- 8.2.7 Others
- 8.3 Europe Biobanking Market (2017-2032) by Country
- 8.3.1 United Kingdom
- 8.3.2 Germany
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Others
- 9 Asia Pacific Biobanking Market (2017-2032)
- 9.1 Asia Pacific Biobanking Market (2017-2032) by Material
- 9.1.1 Market Overview
- 9.1.2 Population-based Biobanks
- 9.1.3 Disease-based Biobanks
- 9.1.4 Academic Biobanks
- 9.1.5 Hospital-based Biobanks
- 9.1.6 Commercial Biobanks
- 9.2 Asia Pacific Biobanking Market (2017-2032) by Sample Type
- 9.2.1 Market Overview
- 9.2.2 Blood Products
- 9.2.3 Human Tissues
- 9.2.4 Nucleic Acids
- 9.2.5 Cell Lines
- 9.2.6 Biological Fluids
- 9.2.7 Others
- 9.3 Asia Pacific Biobanking Market (2017-2032) by Country
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 ASEAN
- 9.3.5 Australia
- 9.3.6 Others
- 10 Latin America Biobanking Market (2017-2032)
- 10.1 Latin America Biobanking Market (2017-2032) by Material
- 10.1.1 Market Overview
- 10.1.2 Population-based Biobanks
- 10.1.3 Disease-based Biobanks
- 10.1.4 Academic Biobanks
- 10.1.5 Hospital-based Biobanks
- 10.1.6 Commercial Biobanks
- 10.2 Latin America Biobanking Market (2017-2032) by Sample Type
- 10.2.1 Market Overview
- 10.2.2 Blood Products
- 10.2.3 Human Tissues
- 10.2.4 Nucleic Acids
- 10.2.5 Cell Lines
- 10.2.6 Biological Fluids
- 10.2.7 Others
- 10.3 Latin America Biobanking Market (2017-2032) by Country
- 10.3.1 Brazil
- 10.3.2 Argentina
- 10.3.3 Mexico
- 10.3.4 Others
- 11 Middle East and Africa Biobanking Market (2017-2032)
- 11.1 Middle East and Africa Biobanking Market (2017-2032) by Material
- 11.1.1 Market Overview
- 11.1.2 Population-based Biobanks
- 11.1.3 Disease-based Biobanks
- 11.1.4 Academic Biobanks
- 11.1.5 Hospital-based Biobanks
- 11.1.6 Commercial Biobanks
- 11.2 Middle East and Africa Biobanking Market (2017-2032) by Sample Type
- 11.2.1 Market Overview
- 11.2.2 Blood Products
- 11.2.3 Human Tissues
- 11.2.4 Nucleic Acids
- 11.2.5 Cell Lines
- 11.2.6 Biological Fluids
- 11.2.7 Others
- 11.3 Middle East and Africa Biobanking Market (2017-2032) by Country
- 11.3.1 Saudi Arabia
- 11.3.2 United Arab Emirates
- 11.3.3 Nigeria
- 11.3.4 South Africa
- 11.3.5 Others
- 12 Regulatory Framework
- 12.1 Regulatory Overview
- 12.1.1 US FDA
- 12.1.2 EU EMA
- 12.1.3 INDIA CDSCO
- 12.1.4 JAPAN PMDA
- 12.1.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication Year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grants Analysis
- 14.1 Analysis by Year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by Departments
- 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Thermo Fisher Scientific Inc.
- 17.1.1 Financial Analysis
- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisitions
- 17.1.5 Certifications
- 17.2 Brooks Automation, Inc.
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisitions
- 17.2.5 Certifications
- 17.3 Qiagen N.V.
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisitions
- 17.3.5 Certifications
- 17.4 Tecan Group Ltd.
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 Hamilton Company
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 Chart Industries, Inc.
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 PHC Holdings Corporation
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisitions
- 17.7.5 Certifications
- 17.8 Becton, Dickinson and Company (BD)
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisitions
- 17.8.5 Certifications
- 17.9 Merck KGaA
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 Panasonic Healthcare Holdings Co., Ltd.
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisitions
- 17.10.5 Certifications
- 17.11 STEMCELL Technologies Inc.
- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisitions
- 17.11.5 Certifications
- 17.12 Lifenet Health
- 17.12.1 Financial Analysis
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisitions
- 17.12.5 Certifications
- 17.13 Promega Corporation
- 17.13.1 Financial Analysis
- 17.13.2 Product Portfolio
- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Mergers and Acquisitions
- 17.13.5 Certifications
- 17.14 Greiner Bio-One International GmbH
- 17.14.1 Financial Analysis
- 17.14.2 Product Portfolio
- 17.14.3 Demographic Reach and Achievements
- 17.14.4 Mergers and Acquisitions
- 17.14.5 Certifications
- 17.15 Lonza Group AG
- 17.15.1 Financial Analysis
- 17.15.2 Product Portfolio
- 17.15.3 Demographic Reach and Achievements
- 17.15.4 Mergers and Acquisitions
- 17.15.5 Certifications
- List not exhaustive
- 18 Global Biobanking Market – Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.